A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder

By Rösler Michael   Fischer Roland   Ammer Richard   Ose Claudia   Retz Wolfgang  

European Archives of Psychiatry and Clinical Neuroscience, Vol. 259, Iss. 2, 2009-02 ,pp. : 120-129

Springer Publishing Company

Access to resources Recommend Favorite

Buspirone Versus Methylphenidate in the Treatment of Attention Deficit Hyperactivity Disorder: A Double-Blind and Randomized Trial

By Davari-Ashtiani Rozita  

Child Psychiatry and Human Development, Vol. 41, Iss. 6, 2010-12 ,pp. : 641-648

Springer Publishing Company

Access to resources Recommend Favorite

Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate

By Rösler Michael  

World Journal of Biological Psychiatry, Vol. 14, Iss. 4, 2013-05 ,pp. : 282-290

Informa Healthcare

Access to resources Recommend Favorite

Bupropion SR vs. Methylphenidate vs. Placebo for Attention Deficit Hyperactivity Disorder in Adults

By Kuperman S.  

Annals of Clinical Psychiatry (after Jan 1, 2004), Vol. 13, Iss. 3, 2001-09 ,pp. : 129-134

Springer Publishing Company

Access to resources Recommend Favorite

Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder

By Aron A.R.   Dowson J.H.   Sahakian B.J.   Robbins T.W.  

Biological Psychiatry, Vol. 54, Iss. 12, 2003-12 ,pp. : 1465-1468

Elsevier

Access to resources Recommend Favorite